2014 Fiscal Year Final Research Report
Analysis of epigenetic changes in hepatocellular carcinoma and an investigation for a new therapeutic modality targeting histone acetylation
| Project/Area Number |
24590993
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MASHINO Tadahiko 慶應義塾大学, 薬学部, 教授 (90165697)
SAITO Yoshimasa 慶應義塾大学, 薬学部, 准教授 (90360114)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Keywords | エピゲノム変化 / ヒストン脱アセチル化酵素阻害薬 / microRNA / C型肝炎ウイルス / 肝細胞癌 / Nrf2 / EZH2 / 培養細胞株 |
|---|
| Outline of Final Research Achievements |
The aim of this study was to investigate a new therapeutic strategy against hepatocellular carcinoma (HCC) and viral infection using epigenetic changes especially by the histone modifier. Cell lines infected with hepatitis C virus (HCV) or replicons were used in this study. Histone deacetylase inhibitor (HDACi), SAHA, inhibited HCV replication by changing host cellular gene expressions as well as decreasing cellular proliferation by inhibiting EZH2 expression. Nrf2 expression was important for long-term HCV infection in the cell line, and expression levels of Nrf2, EZH2 and miR-122 mutually affect proliferation of cells and also HCV.
|
| Free Research Field |
消化器内科学
|
